TBI 1201

Drug Profile

TBI 1201

Alternative Names: MAGE-A4 antigen-specific RetroNectin® TCR gene therapy - Takara Bio; MAGE-A4 antigen-specific TCR modified lymphocytes - Takara Bio; MAGE-A4 TCR-transduced T-cell therapy - Takara Bio; MAGE-A4-targeted T-cell therapy - Takara Bio; TBI-1201

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Takara Bio
  • Developer Mie University; Takara Bio
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • No development reported Oesophageal cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Oesophageal-cancer(Monotherapy, Second-line therapy or greater) in Japan (SC)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Oesophageal-cancer(Combination therapy, Second-line therapy or greater) in Japan (IV)
  • 01 Apr 2014 Phase-I clinical trials in Solid tumours (second-line therapy or greater; recurrent; refractory metastatic disease) in Japan (IV) (NCT02096614)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top